Resubmitted FDA filing advances off-the-shelf EBV-specific T-cell therapy tab-cel for relapsed EBV+ PTLD after transplant, with longer follow-up.
Feature|Articles|October 1, 2026
Q4 2026 Oncology Outlook: Key FDA Decisions to Watch
Author(s)Targeted Oncology Staff
Fact checked by: Andrea Eleazar, MHS
Late 2026 FDA oncology rulings may reshape care—from CSF-1R and ALK drugs to oral SERDs and BCMA CAR T breakthroughs.
Advertisement
Advertisement
The final quarter of 2026 is expected to bring several consequential FDA decisions in oncology, spanning targeted therapies, antibody-based treatments, and chimeric antigen receptor (CAR) T-cell therapy. The applications cover a broad range of disease settings, from rare tumors such as tenosynovial giant cell tumor (TGCT) and gastrointestinal stromal tumors (GIST) to biomarker-defined populations in lung, breast, and prostate cancers. Several decisions could also introduce therapies into earlier lines of treatment or add new options for patients with limited choices after disease progression.
Related to this article
Resection with cesium-131 tile-based radiation therapy prolonged time to surgical bed recurrence vs resection with stereotactic radiation in the phase 3 ROADS trial.
Degevma was approved for skeletal-related events in adults with bone metastases, giant cell tumor of bone, and the treatment of hypercalcemia of malignancy.
FDA fast-tracks plinabulin plus docetaxel for post-immunotherapy non-squamous NSCLC, as DUBLIN-4 phase 3 targets survival gains.
September brought accelerated approvals in ESR1-mutant breast cancer and HER2-mutant non–small cell lung cancer, a Galleri panel vote, and a withdrawn I-DXd application.
The application is supported by the phase 3 SAFFRON trial, in which savolitinib plus osimertinib improved progression-free and overall survival vs chemotherapy.
Proton therapy did not improve overall survival vs photon therapy in advanced hepatocellular carcinoma in the phase 3 NRG-GI003 trial.
Published findings from the ASPEN-06 trial of evorpacept in previously treated HER2+ gastric cancers included exploratory analyses suggesting CD47 is a predictive biomarker for benefit with the targeted agent.
Advertisement
Advertisement